Search

Your search keyword '"GASBARRINI, Antonio"' showing total 6,108 results

Search Constraints

Start Over You searched for: Author "GASBARRINI, Antonio" Remove constraint Author: "GASBARRINI, Antonio"
6,108 results on '"GASBARRINI, Antonio"'

Search Results

6. Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients

7. List of contributors

8. Current treatments of alcohol use disorder

12. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

13. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study

14. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

15. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

19. A single-center prospective analysis of the impact of glucose metabolism on pancreatic fistula onset after pancreaticoduodenectomy for periampullary tumors

22. Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis

25. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

26. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations

27. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

30. Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes

31. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

32. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

42. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

45. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

48. Radiomics could predict surgery at 10 years in Crohn's disease

49. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Catalog

Books, media, physical & digital resources